MYGN
Myriad Genetics, Inc.$4.32-0.32 (-6.80%)Prev Close$4.63·MCap$431.6M·P/E—·Vol804.8K·Yield—
▲
Buys (12M)
3
$722.2K
▼
Sells (12M)
1
$66.8K
◆
Net Activity
Net Buyer
$655.4K
●
Active Insiders
4
last 12 mo
Over the past 12 months, insider activity at Myriad Genetics, Inc. (MYGN) has been dominated by buying, with 3 insider purchases totaling $722.2K and 1 insider sale totaling $66.8K. The most recent insider transaction was by Kumar Rashmi (director), who sold $66.8K worth of shares on Jun 9, 2026. Myriad Genetics, Inc. operates in the Healthcare sector, within the Medical - Diagnostics & Research industry, with a market cap of $431.6M.
MYGN Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Kumar Rashmi | director | Sell | 15,000 | $4.46 | $66.8K | 171,889 |
| May 14, 2026 | Bisaro Paul | director | Buy | 7,500 | $3.69 | $27.6K | 97,441 |
| Mar 9, 2026 | Raha Samraat S. | director, officer: President and CEO | Buy | 40,000 | $5.00 | $199.8K | 493,104 |
| Feb 27, 2026 | Phanstiel S. Louise | director | Buy | 104,507 | $4.73 | $494.7K | 281,951+59% |
| Oct 11, 2024 | DIAZ PAUL J | President and CEO | Sell | 15,000 | $22.93 | $343.9K | 962,378 |
| Sep 12, 2024 | DIAZ PAUL J | President and CEO | Sell | 15,000 | $26.72 | $400.8K | 977,378 |
| Sep 12, 2024 | Muzzey Dale | Chief Scientific Officer | Sell | 2,100 | $26.17 | $55.0K | 108,013 |
| Sep 9, 2024 | Dreismann Heinrich | Director | Sell | 10,000 | $27.05 | $270.5K | 121,648 |
| Sep 4, 2024 | Reitan Colleen F | Director | Sell | 46,012 | $27.95 | $1.29M | 42,533-52% |
| Aug 23, 2024 | Ancona Margaret | SVP, Chief of Staff | Sell | 11,538 | $27.82 | $321.0K | 79,366 |
| Aug 20, 2024 | Kumar Rashmi | Director | Sell | 7,500 | $28.01 | $210.1K | 77,392 |
| Jun 4, 2024 | SPIEGELMAN DANIEL K | Director | Sell | 7,576 | $22.05 | $167.0K | 36,705 |
| May 15, 2024 | DIAZ PAUL J | President and CEO | Sell | 227,844 | $25.14 | $5.73M | 1,236,166 |
| May 15, 2024 | Newcomer Lee Nisley | Director | Sell | 6,200 | $25.30 | $156.9K | 66,650 |
| Dec 5, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 30,000 | $19.09 | $572.8K | 291,812 |
| Nov 3, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 30,000 | $15.69 | $470.6K | 321,812 |
| Jun 2, 2023 | SPIEGELMAN DANIEL K | Director | Sell | 8,638 | $23.01 | $198.8K | 40,493 |
| Mar 28, 2023 | Lambert Nicole | Chief Operating Officer | Sell | 6,433 | $23.48 | $151.0K | 240,506 |
| Mar 3, 2023 | Lambert Nicole | Chief Operating Officer | Sell | 13,184 | $22.74 | $299.8K | 215,220 |
| Mar 3, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 15,000 | $22.55 | $338.3K | 337,885 |
| Jan 23, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 9,400 | $20.04 | $188.4K | 364,107 |
| Jan 19, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 600 | $20.01 | $12.0K | 373,507 |
| Dec 28, 2022 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 20,000 | $15.15 | $303.0K | 374,107 |
| Jun 6, 2022 | SPIEGELMAN DANIEL K | Director | Sell | 6,424 | $19.25 | $123.7K | 33,980 |
| Mar 1, 2022 | Hart Jayne B. | Chief People Officer | Sell | 10,500 | $25.00 | $262.5K | 165,878 |
| Oct 4, 2021 | Lambert Nicole | See Remarks | Sell | 1,420 | $31.57 | $44.8K | 176,652 |
| Sep 27, 2021 | Lambert Nicole | See Remarks | Sell | 10,112 | $33.10 | $334.7K | 178,072 |
| Sep 27, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 200 | $35.06 | $7.0K | 288,515 |
| Sep 21, 2021 | Hart Jayne B. | Chief People Officer | Sell | 67,446 | $33.72 | $2.27M | 89,616-43% |
| Aug 30, 2021 | Lambert Nicole | See Remarks | Sell | 945 | $34.50 | $32.6K | 127,051 |
| Aug 25, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 80,000 | $35.32 | $2.83M | 232,550-26% |
| Aug 6, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 28,225 | $35.57 | $1.00M | 232,550 |
| Aug 6, 2021 | Phanstiel S. Louise | Director | Sell | 47,881 | $35.04 | $1.68M | 61,646-44% |
| Aug 5, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 100,000 | $34.68 | $3.47M | 232,550-30% |
| Aug 5, 2021 | LANGER DENNIS | Director | Sell | 30,000 | $34.75 | $1.04M | 89,527-25% |
| Aug 5, 2021 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 14,983 | $35.14 | $526.5K | 324,942 |
| Jul 14, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 93,295 | $33.64 | $3.14M | 232,550-29% |
| Jul 12, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 50,000 | $32.62 | $1.63M | 232,550 |
| Jul 8, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 32,308 | $32.27 | $1.04M | 232,550 |
| Jun 30, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 6,812 | $32.39 | $220.6K | 232,550 |
| Jun 28, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 83,372 | $31.96 | $2.66M | 265,922 |
| Jun 17, 2021 | SPIEGELMAN DANIEL K | Director | Sell | 3,139 | $30.52 | $95.8K | 23,129 |
| Jun 1, 2021 | SPIEGELMAN DANIEL K | Director | Sell | 7,142 | $28.99 | $207.0K | 13,420-35% |
| May 5, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 19,360 | $31.97 | $618.9K | 265,922 |
| Apr 28, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 40,000 | $31.47 | $1.26M | 265,922 |
| Apr 20, 2021 | Lambert Nicole | See Remarks | Sell | 6,649 | $27.01 | $179.6K | 135,009 |
| Mar 30, 2021 | Hart Jayne B. | Chief People Officer | Sell | 58,000 | $30.00 | $1.74M | 80,128-42% |
MYGN Insider Buying Activity
The following table shows recent insider purchases of Myriad Genetics, Inc. (MYGN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| May 14, 2026 | Bisaro Paul | director | Buy | 7,500 | $3.69 | $27.6K | 97,441 |
| Mar 9, 2026 | Raha Samraat S. | director, officer: President and CEO | Buy | 40,000 | $5.00 | $199.8K | 493,104 |
| Feb 27, 2026 | Phanstiel S. Louise | director | Buy | 104,507 | $4.73 | $494.7K | 281,951+59% |
MYGN Insider Selling Activity
The following table shows recent insider sales of Myriad Genetics, Inc. (MYGN) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Kumar Rashmi | director | Sell | 15,000 | $4.46 | $66.8K | 171,889 |
| Oct 11, 2024 | DIAZ PAUL J | President and CEO | Sell | 15,000 | $22.93 | $343.9K | 962,378 |
| Sep 12, 2024 | DIAZ PAUL J | President and CEO | Sell | 15,000 | $26.72 | $400.8K | 977,378 |
| Sep 12, 2024 | Muzzey Dale | Chief Scientific Officer | Sell | 2,100 | $26.17 | $55.0K | 108,013 |
| Sep 9, 2024 | Dreismann Heinrich | Director | Sell | 10,000 | $27.05 | $270.5K | 121,648 |
| Sep 4, 2024 | Reitan Colleen F | Director | Sell | 46,012 | $27.95 | $1.29M | 42,533-52% |
| Aug 23, 2024 | Ancona Margaret | SVP, Chief of Staff | Sell | 11,538 | $27.82 | $321.0K | 79,366 |
| Aug 20, 2024 | Kumar Rashmi | Director | Sell | 7,500 | $28.01 | $210.1K | 77,392 |
| Jun 4, 2024 | SPIEGELMAN DANIEL K | Director | Sell | 7,576 | $22.05 | $167.0K | 36,705 |
| May 15, 2024 | DIAZ PAUL J | President and CEO | Sell | 227,844 | $25.14 | $5.73M | 1,236,166 |
| May 15, 2024 | Newcomer Lee Nisley | Director | Sell | 6,200 | $25.30 | $156.9K | 66,650 |
| Dec 5, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 30,000 | $19.09 | $572.8K | 291,812 |
| Nov 3, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 30,000 | $15.69 | $470.6K | 321,812 |
| Jun 2, 2023 | SPIEGELMAN DANIEL K | Director | Sell | 8,638 | $23.01 | $198.8K | 40,493 |
| Mar 28, 2023 | Lambert Nicole | Chief Operating Officer | Sell | 6,433 | $23.48 | $151.0K | 240,506 |
| Mar 3, 2023 | Lambert Nicole | Chief Operating Officer | Sell | 13,184 | $22.74 | $299.8K | 215,220 |
| Mar 3, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 15,000 | $22.55 | $338.3K | 337,885 |
| Jan 23, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 9,400 | $20.04 | $188.4K | 364,107 |
| Jan 19, 2023 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 600 | $20.01 | $12.0K | 373,507 |
| Dec 28, 2022 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 20,000 | $15.15 | $303.0K | 374,107 |
| Jun 6, 2022 | SPIEGELMAN DANIEL K | Director | Sell | 6,424 | $19.25 | $123.7K | 33,980 |
| Mar 1, 2022 | Hart Jayne B. | Chief People Officer | Sell | 10,500 | $25.00 | $262.5K | 165,878 |
| Oct 4, 2021 | Lambert Nicole | See Remarks | Sell | 1,420 | $31.57 | $44.8K | 176,652 |
| Sep 27, 2021 | Lambert Nicole | See Remarks | Sell | 10,112 | $33.10 | $334.7K | 178,072 |
| Sep 27, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 200 | $35.06 | $7.0K | 288,515 |
| Sep 21, 2021 | Hart Jayne B. | Chief People Officer | Sell | 67,446 | $33.72 | $2.27M | 89,616-43% |
| Aug 30, 2021 | Lambert Nicole | See Remarks | Sell | 945 | $34.50 | $32.6K | 127,051 |
| Aug 25, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 80,000 | $35.32 | $2.83M | 232,550-26% |
| Aug 6, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 28,225 | $35.57 | $1.00M | 232,550 |
| Aug 6, 2021 | Phanstiel S. Louise | Director | Sell | 47,881 | $35.04 | $1.68M | 61,646-44% |
| Aug 5, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 100,000 | $34.68 | $3.47M | 232,550-30% |
| Aug 5, 2021 | LANGER DENNIS | Director | Sell | 30,000 | $34.75 | $1.04M | 89,527-25% |
| Aug 5, 2021 | Riggsbee Richard Bryan | Chief Financial Officer | Sell | 14,983 | $35.14 | $526.5K | 324,942 |
| Jul 14, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 93,295 | $33.64 | $3.14M | 232,550-29% |
| Jul 12, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 50,000 | $32.62 | $1.63M | 232,550 |
| Jul 8, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 32,308 | $32.27 | $1.04M | 232,550 |
| Jun 30, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 6,812 | $32.39 | $220.6K | 232,550 |
| Jun 28, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 83,372 | $31.96 | $2.66M | 265,922 |
| Jun 17, 2021 | SPIEGELMAN DANIEL K | Director | Sell | 3,139 | $30.52 | $95.8K | 23,129 |
| Jun 1, 2021 | SPIEGELMAN DANIEL K | Director | Sell | 7,142 | $28.99 | $207.0K | 13,420-35% |
| May 5, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 19,360 | $31.97 | $618.9K | 265,922 |
| Apr 28, 2021 | LANCHBURY JERRY S | Chief Scientific Officer | Sell | 40,000 | $31.47 | $1.26M | 265,922 |
| Apr 20, 2021 | Lambert Nicole | See Remarks | Sell | 6,649 | $27.01 | $179.6K | 135,009 |
| Mar 30, 2021 | Hart Jayne B. | Chief People Officer | Sell | 58,000 | $30.00 | $1.74M | 80,128-42% |
MYGN Insiders
Similar Stocks to MYGN
TMO
Thermo Fisher Scientific Inc.
$469.78-1.27%
$175.70B
DHR
Danaher Corporation
$180.21-0.32%
$130.44B
A
Agilent Technologies, Inc.
$129.35-0.18%
$38.25B
NTRA
Natera, Inc.
$212.30-3.16%
$30.84B
ILMN
Illumina, Inc.
$161.55-2.79%
$23.91B
WAT
Waters Corporation
$355.76-1.11%
$23.68B
DGX
Quest Diagnostics Incorporated
$203.41-0.22%
$21.83B
LH
Labcorp Holdings Inc.
$265.96+0.23%
$21.48B